Atripla

Antiviral
Favicons?domain=wwwCentre Daily Times | October 21, 2009

Earnings Preview: Bristol-Myers 3Q earnings report

Meanwhile, she said investor focus remains on cost savings, sales of four growth drivers - Plavix, Orencia for rheumatoid arthritis, leukemia drug Sprycel and combination HIV drug Atripla - along with some key drugs in development. Those...

In this article: Bristol-Myers, Plavix, Revenue, Abilify, Food and Drug Administration, AstraZeneca PLC, Bristol, Ipilimumab, and Otsuka Pharmaceutical Co.

Connections-toggle
Filter by
or